DK2046349T3 - Behandling af excessiv neovaskularisering - Google Patents

Behandling af excessiv neovaskularisering Download PDF

Info

Publication number
DK2046349T3
DK2046349T3 DK07784641.8T DK07784641T DK2046349T3 DK 2046349 T3 DK2046349 T3 DK 2046349T3 DK 07784641 T DK07784641 T DK 07784641T DK 2046349 T3 DK2046349 T3 DK 2046349T3
Authority
DK
Denmark
Prior art keywords
cells
cell
stro
leakage
laser
Prior art date
Application number
DK07784641.8T
Other languages
English (en)
Inventor
Piroska Elizabeth Rakoczy
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of DK2046349T3 publication Critical patent/DK2046349T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Claims (8)

1. Anvendelse af voksne mesenchymale STRO-1bn9ht-precursorceller (MPC), eller ekspanderede celler deraf, i fremstillingen af et medikament til behandling eller forebyggelse af makuladedegeneration eller diabetisk retinopati hos et individ.
2. Anvendelse ifølge krav 1, hvor makuladedegenerationen er tør aldersrelateret makuladedegeneration eller våd aldersrelateret makuladedegeneration.
3. Anvendelse ifølge krav 1 eller krav 2, hvor stamcellerne er opnået fra knoglemarv.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor mindst nogle af cellerne er genetisk modificerede.
5. Voksne mesenchymale STRO-1-precursorceller (MPC), eller ekspanderede celler deraf, til anvendelse i behandling eller forebyggelse af makuladedegeneration eller diabetisk retinopati.
6. Voksne mesenchymale STRO-1-precursorceller (MPC), eller ekspanderede celler deraf, ifølge krav 5, hvor makuladedegenerationen er tør aldersrelateret makuladedegeneration eller våd aldersrelateret makuladedegeneration.
7. Voksne mesenchymale STRO-1-precursorceller (MPC), eller ekspanderede celler deraf, ifølge krav 5 eller krav 6, hvor stamcellerne er opnået fra knoglemarv.
8. Voksne mesenchymale STRO-1-precursorceller (MPC), eller ekspanderede celler deraf, ifølge et hvilket som helst af kravene 5 til 7, hvor mindst nogle af cellerne er genetisk modificerede.
DK07784641.8T 2006-07-12 2007-07-12 Behandling af excessiv neovaskularisering DK2046349T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83064906P 2006-07-12 2006-07-12
US83065106P 2006-07-12 2006-07-12
PCT/AU2007/000974 WO2008006168A1 (en) 2006-07-12 2007-07-12 Treatment of excessive neovascularization

Publications (1)

Publication Number Publication Date
DK2046349T3 true DK2046349T3 (da) 2015-12-21

Family

ID=38922855

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07784641.8T DK2046349T3 (da) 2006-07-12 2007-07-12 Behandling af excessiv neovaskularisering

Country Status (10)

Country Link
US (3) US20100111910A1 (da)
EP (1) EP2046349B1 (da)
JP (3) JP6041456B2 (da)
KR (1) KR101475303B1 (da)
CN (1) CN101516385B (da)
AU (1) AU2007272313B2 (da)
CA (1) CA2657308C (da)
DK (1) DK2046349T3 (da)
HK (1) HK1129600A1 (da)
WO (1) WO2008006168A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007272313B2 (en) * 2006-07-12 2013-11-21 Mesoblast, Inc. Treatment of excessive neovascularization
JP2011526892A (ja) * 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
US8309343B2 (en) 2008-12-01 2012-11-13 Baxter International Inc. Apparatus and method for processing biological material
CN103079578B (zh) * 2010-07-02 2017-02-15 迈索布拉斯特股份有限公司 治疗移植物抗宿主疾病的方法
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
EP2729562B1 (en) 2011-07-06 2018-04-18 Cell Therapy Limited Progenitor cells of mesodermal lineage
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US20200368291A1 (en) 2017-12-28 2020-11-26 Kaneka Corporation Cell population including adhesive stem cells, production method therefor and pharmaceutical composition
CN113573720A (zh) * 2019-01-03 2021-10-29 迈索布拉斯特国际有限公司 提高视力的方法
JPWO2020251020A1 (da) 2019-06-14 2020-12-17

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216439A1 (en) * 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
US6162428A (en) * 1997-02-12 2000-12-19 Layton Bioscience, Inc. hNT-neuron human neuronal cells to replace ganglion cells
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
ATE514772T1 (de) * 1999-08-05 2011-07-15 Abt Holding Co Multipotente erwachsene stammzellen und verfahren zu deren isolierung
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
WO2002086104A1 (en) * 2001-04-24 2002-10-31 Dolores Baksh Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
DK1542536T3 (da) * 2002-07-25 2012-01-23 Scripps Research Inst Hæmatopoietiske stamceller og fremgangsmåder til behandling af neovaskulære øjensygdomme dermed
AU2003295473A1 (en) * 2002-11-13 2004-06-03 Wackvom Limited Method of preparing anti-angiogenic drug from cartillage and chondrocytes and methods of use
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
CN101506355B (zh) * 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
DK1935976T3 (da) * 2005-02-24 2012-04-10 Scripps Research Inst Transficerede myeloid-lignende celler til behandling af retinopati ved for tidlig fødsel og dermed relaterede sygdomme
EP1869075B1 (en) * 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
ES2654428T3 (es) * 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
PL1888123T3 (pl) * 2005-06-08 2013-06-28 Janssen Biotech Inc Terapia komórkowa chorób degeneracyjnych oka
US20070128174A1 (en) * 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality
AU2007272313B2 (en) * 2006-07-12 2013-11-21 Mesoblast, Inc. Treatment of excessive neovascularization

Also Published As

Publication number Publication date
JP2016121142A (ja) 2016-07-07
JP2014237647A (ja) 2014-12-18
KR101475303B1 (ko) 2014-12-23
AU2007272313A1 (en) 2008-01-17
US20180369286A1 (en) 2018-12-27
JP2009542727A (ja) 2009-12-03
CN101516385B (zh) 2013-07-10
CA2657308C (en) 2017-06-27
US20100111910A1 (en) 2010-05-06
CN101516385A (zh) 2009-08-26
CA2657308A1 (en) 2008-01-17
EP2046349A1 (en) 2009-04-15
JP6041456B2 (ja) 2016-12-07
EP2046349B1 (en) 2015-09-09
US20230165901A1 (en) 2023-06-01
HK1129600A1 (en) 2009-12-04
AU2007272313B2 (en) 2013-11-21
EP2046349A4 (en) 2010-11-10
KR20090033384A (ko) 2009-04-02
WO2008006168A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
US20230165901A1 (en) Treatment of excessive neovascularization
Ferrari et al. Gene therapy using haematopoietic stem and progenitor cells
AU2009269149B2 (en) Treatment of eye diseases and excessive neovascularization using a combined therapy
AU2018201231B2 (en) Treatment of pulmonary arterial hypertension with mesenchymal stem cells
JP6709834B2 (ja) プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置
AU2022203629A1 (en) Methods of treating mitochondrial disorders
AU2016201801A1 (en) Treatment of excessive neovascularization
AU2014200774A1 (en) Treatment of excessive neovascularization
López et al. Preliminary study on non-viral transfection of F9 (factor IX) gene by nucleofection in human adipose-derived mesenchymal stem cells
Soper et al. Transplanted ER-MP12hi20− 58med/hi myeloid progenitors produce resident macrophages from marrow that are therapeutic for lysosomal storage disease
AU2021239908A1 (en) Methods of treating mitochondrial disorders